MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
Abstract HER2-positive (HER2 +) breast cancer patients that do not respond to targeted treatment have a poor prognosis. The effects of targeted treatment on endogenous microRNA (miRNA) expression levels are unclear. We report that responsive HER2 + breast cancer cell lines had a higher number of miR...
Guardado en:
Autores principales: | Lisa Svartdal Normann, Miriam Ragle Aure, Suvi-Katri Leivonen, Mads Haugland Haugen, Vesa Hongisto, Vessela N. Kristensen, Gunhild Mari Mælandsmo, Kristine Kleivi Sahlberg |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0b40ee361d9441319955d2b6754721b1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
por: Jernström S, et al.
Publicado: (2017) -
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors.
por: Espen Enerly, et al.
Publicado: (2011) -
Human papillomavirus 16 E5 modulates the expression of host microRNAs.
por: Dario Greco, et al.
Publicado: (2011) -
Identification of microRNAs inhibiting TGF-β-induced IL-11 production in bone metastatic breast cancer cells.
por: Sirkku Pollari, et al.
Publicado: (2012) -
TGF-β-elicited induction of tissue inhibitor of metalloproteinases (TIMP)-3 expression in fibroblasts involves complex interplay between Smad3, p38α, and ERK1/2.
por: Suvi-Katri Leivonen, et al.
Publicado: (2013)